FDA expands Abilify use to schizophrenic teens

11/6/2007 | Wall Street Journal (free content), The · Yahoo!

The FDA has granted expanded approval to Bristol-Myers Squibb's antipsychotic drug Abilify for treatment of schizophrenic adolescents aged 13 to 17. The decision follows a six-week, 13-country study that showed the drug performed significantly better than placebo.

View Full Article in:

Wall Street Journal (free content), The · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ